Senate committee advances AB 260 to shield medication-abortion providers, prescriptions

Assemblymember Aguiar Curry introduced AB 260, a measure she described as protecting access to medication abortion in California, at the June 23 meeting of the California State Senate Business, Professions and Economic Development Committee. The panel voted to move the bill to the Senate Appropriations Committee.

The bill—s author, Assemblymember Aguiar Curry, told the committee AB 260 would protect health care providers, pharmacies, clinics and hospitals from disciplinary or licensing consequences for legally providing mifepristone and would allow prescription labels to omit patient and prescriber names. "This bill protects safe and legal reproductive health here in California," Aguiar Curry said, arguing the measure is "necessary to protect access to health care, to protect providers, to protect the right to choose."

Adrianna Benedict, general counsel for Hey Jane, a primarily telehealth abortion provider, and Tiffany Brokaw, deputy attorney general representing Attorney General Rob Bonta, testified in support. Benedict said threats to providers have escalated and cited recent federal litigation and enforcement actions as heightening risk. Brokaw told the committee that AB 260 would shield providers from liability, authorize pharmacists to dispense medication abortion without patient name or prescriber name on the label and require health plans to continue covering medication abortion.

Greg Burt of the California Family Council testified in opposition, saying the bill—s labeling and privacy provisions would reduce transparency and accountability. Burt disputed safety claims about mifepristone and raised concerns about access to records for investigations.

After public testimony, Senator Menjivar moved the committee—s motion to pass AB 260 to the Senate Appropriations Committee. The committee—s recorded tally (reported by the committee clerk) was 6 yes, 1 no; the motion was reported out of committee for further consideration in appropriations.

Why it matters: Committee supporters said AB 260 responds to legal and enforcement risks they say have grown since the U.S. Supreme Court—s Dobbs decision and to a recent federal court ruling cited in testimony (Pearl v. HHS) that affected a federal reproductive-health privacy rule. Supporters said the measure would preserve access to medication abortion for Californians and protect providers who lawfully prescribe medication.

Next steps: AB 260 was moved to the Senate Appropriations Committee for fiscal review and further hearings.